Other major modification was the categorization of AML with myelodysplasia-related gene (MDS) mutations (ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2) as adverse genetic risk. Here, ASXL1 is linked to acute myeloid leukemia.